Podium Presentations
 
Podium Session I
Sunday 9 November 2008, 15:15-16:15
Economic Evaluations I 
EE1  DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS: DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION? 
Van Helvoort-Postulart D1, Dellaert B2, Van der Weijden T3, Von Meyen M1, Dirksen CD1
1Maastricht University Medical Center, Maastricht, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Maastricht University, Maastricht, The Netherlands
EE2  STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES COMPLICATIONS 
Minshall ME1, Pelletier EM2, Smith PJ3, Forma FM4
1IMS Health, Noblesville, IN, USA, 2IMS Health Consulting, Watertown, MA, USA, 3PharMetrics, a unit of IMS, Watertown, MA, USA, 4Novo Nordisk Inc, Princeton, NJ, USA
EE3  VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS C VIRUS 
Davis KL1, Mitra D1, Medjedovic J2, Beam C3, Rustgi V4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA
EE4  CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS 
Le Lay K1, Boussetta S1, Moldofsky H2, Taieb C1
1Pierre Fabre, Boulogne, France, 2Centre for Sleep and Chronobiology, Toronto, ON, Canada
 
Performance of HTA Agencies 
HT1  A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES 
Schwarzer R, Siebert U
UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T, Tirol, Austria 
HT2  UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS - ECONOMIC CRITICISMS 
Karia R, Plested M, Cann K, Zwaferink H
Heron Evidence Development Ltd, Letchworth Garden City, UK 
HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS: NICE, SMC, CADTH AND PBAC 
  Cann K, Karia R, Plested M, Samuels E
  Heron Evidence Development Ltd, Letchworth Garden City, UK 
HT4  HEALTH TECHNOLOGY ASSESSMENTS: ARE THEY RELEVANT TO CLINICAL PRACTICE? 
Zhang B1, Van Staa TP2
1General Practice Research Database, London, Middlesex, UK, 2General Practice Research Database, London, UK 
 
Medical Device Economic Evaluations 
MD1  HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND 
Clegg JP1, Wéry E1, Karamalis M2, Pokorski J2, Mlynarski W3, Valentine WJ1, Goodall G4
1IMS Health, Allschwil, Switzerland, 2Medtronic Poland Sp. z o.o, Warsaw, Poland, 3Medical University of Lodz, Lodz, Poland, 4IMS Health, Basel, Switzerland
MD2  COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR® DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY ARTERY BYPASS GRAFT SURGERY IN SPAIN 
Rodriguez Barrios JM1, Moreu J2, Cequier A3, Brosa M4, Vazquez N5, Hernandez J6, Crespo C7, Brasseur P8
1Medtronic Iberia, Madrid, Madrid, Spain, 2Virgen de la Salud Hospital, Toledo, Toledo, Spain, 3Belvitge Hospital, Barcelona, Barcelona, Spain, 4Oblikue, Barcelona, Barcelona, Spain, 5Juan Canalejo Hospital, A Coruna, A Coruna, Spain, 6Malaga Clinic Hospital, Malaga, Malaga, Spain, 7Oblikue Consulting, Barcelona, Spain, 8Medtronic Sarl, Tolochenaz, Switzerland 
MD3  COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM'S PERSPECTIVE IN AUSTRIA 
Tuschel A, Meissl M, Ogon M
Orthopaedic Hospital Vienna Speising, Vienna, Austria 
MD4  UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY: COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY 
Murthy A1, Tsintzos S2
1Medtronic International, Tolochenaz, Vaud, Switzerland, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland 
 
Mental Health I (Attention-Deficit/Hyperactivity Disorder in Europe) 
MH1  HOW MUCH SHOULD WE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? 
Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Persson U4, Santosh PJ5, Trott GE6, MTA Cooperative Group _7
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Erasmus MC, Rotterdam, The Netherlands, 3Columbia University, New York, NY, USA, 4The Swedish Institute for Health Economics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg, Aschaffenburg, Germany, 7National Institute of Mental Health, Bethesda, MD, USA 
MH2  THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOOD TO ADULTHOOD: A MEDICAID STUDY 
Chen H, Sudharshan L
University of Houston, Houston, TX, USA 
MH3  COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS IN FINLAND: AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT) 
Schlander M1, Hjelmgren J2
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Janssen-Cilag AB, Sollentuna, Sweden 
MH4  HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY – IMPACT OF COEXISTING CONDITIONS 
Schlander M1, Schwarz O1, Trott GE2, Viapiano M3, Bonauer N3
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University of Wuerzburg, Aschaffenburg, Germany, 3Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany 
 
Quality of Life/Preference-Based Measures I
QL1  AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES: REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION 
Wild D1, Martin M2, Hareendran A3, von Maltzahn R1
1Oxford Outcomes Ltd, Oxford, UK, 2Health Research Associates Inc, Seattle, WA, USA, 3Pfizer, Ltd, Sandwich, UK 
QL2  TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES 
Fernandez N1, Grataloup G1, Posner K2
1Mapi Research Institute, Lyon, France, 2New York State Psychiatric Institute, New York, NY, USA 
QL3  ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS 
Anfray C, Emery MP
Mapi Research Trust, Lyon, France 
QL4  PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA 
Kontodimopoulos N1, Paliouras D2, Pappa E1, Papadopoulos AA3, Aletras VH4, Niakas D1
1Hellenic Open University, Patras, Greece, 2Theagenio Cancer Hospital, Thessalonica, Greece, 3Attikon University Hospital, Athens, Greece, 4University of Macedonia, Thessalonica, Greece
<
 
Podium Session II
Sunday 9 November 2008, 16:30-17:30
Cardiovascular Disease Evaluations
CV1  WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS? 
Eisenstein EL1, Cowper PA1, Bae JP2, Kong DF1, Ramaswamy K3, Anstrom KJ1
1Duke Clinical Research Institute, Durham, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Daiichi Sankyo Inc, Parsippany, NJ, USA 
CV2  A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ATRIAL FIBRILLATION: AF-QOL 
Arribas F1, Ormaetxe JM2, Peinado R3, Fernandez C4, Ramírez P4, Badia XB5, Lara N5
1Hospital 12 de Octubre, Madrid, Spain, 2Hospital de Basurto, Bilbao, Spain, 3Hospital La Paz, Madrid, Spain, 4MEDA Pharma, Madrid, Spain, 5IMS Health, Barcelona, Spain 
CV3  PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES 
Sorensen SV1, Webb SF2, Burge RT2
1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA 
CV4  COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE THE NETHERLANDS 
Nuijten MJ1, Redekop WK2
1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands 
 
Economic Evaluations II 
PRS8 TOTAL COSTS OF TOBACCO FOR SOCIETY – WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS?
  Reissell E1, Herse F1, Väänänen JJP1, Linden K2, Kotomäki T2, Parvinen PMT1
  1Nordic Healthcare Group, Helsinki, Finland, 2Pfizer Oy, Helsinki, Finland
   
EE6  COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK 
Ray JA1, Carr E1, Geary U2
1F. Hoffmann - La Roche, Basel, Switzerland, 2Roche Products Limited, Hertfordshire, UK 
EE7  ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN ITALY: THE NATIONAL AND REGIONAL LEVEL 
Cavallo M1, Cipriani F2, Demarteau N3, Gerzeli S1, Marocco A2, Bamfi F2
1Bocconi University, Milano, Italy, 2GlaxoSmithKline Spa, Verona, Italy, 3GlaxoSmithKline Biologicals, Wavre, Belgium 
EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE 
Millar DR1, Ducournau P2, McDonald A3
1Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Western Infirmary, Glasgow, UK 
 
Mental Health II (Schizophrenia in Europe) 
MH5  EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA 
Maurino J1, Montes JM2, Saiz Ruiz J3, Claret J4, Diez T1
1AstraZeneca, Madrid, Spain, 2Hospital del Sureste, Arganda del Rey, Spain, 3Hospital Ramon y Cajal, Madrid, Spain, 4Fundació Hospital de Día Nou Barris, Barcelona, Spain 
MH6  ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS FROM THE COMETA STUDY 
Mantovani LG1, Ferrannini L2, Mencacci C3, Pirfo E4, Bernareggi M5, Giustra MG5, Berto P6, Sturkenboom MC7, Scalone L8
1University of Naples, Federico II, Naples, Italy, 2Mental Health Department ASL 3, Genova, Italy, 3Mental Health Department, Milan, NA, Italy, 4Mental Health Department G. Maccacaro, Torino, NA, Italy, 5Janssen-Cilag SpA, Cologno Monzese, Milan, NA, Italy, 6PBE consulting, Verona, Italy, 7Erasmus University Medical Center, Soest, The Netherlands, 8Centre of Pharmacoeconomics, Milan, Italy 
MH7  PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY: A MIXED METHODS APPROACH TO CAPTURING THE PATIENT'S PERSPECTIVE 
Kinter ET1, Rudolph I2, Schmeding A2, Bridges JF1
1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Janssen-Cilag GmbH, Neuss, Germany 
MH8  DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE: REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) 
Geitona M1, Kousoulakou C2, Ollandezos M3, Papanicolaou S4, Athanasakis K3, Tsiantou V3, Kyriopoulos J3
1University of Thessaly, Volos, Greece, 2Foundation for Economic and Industrial Research, Athens, Greece, 3National School of Public Health, Athens, Greece, 4Janssen-Cilag Pharmaceutical SACI, Athens, Attika, Greece 
 
Modelling in Economic Evaluation 
MO1  ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS 
Al MJ1, Welte R2
1Erasmus MC, Rotterdam, The Netherlands, 2GlaxoSmithKline, Munich, Germany 
MO2  INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES: DETERMINISTIC AND PROBABILISTIC APPROACHES 
Taylor DC1, Kruzikas D2, Pawar V3, Gilmore K1, Naik S1, Weinstein MC4
1i3 Innovus, Medford, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA, 3Innovus Research, Inc, Medford, MA, USA, 4i3 Innovus Research Inc., Harvard School of Public Health, Harvard Medical School, Boston, MA, USA 
MO3  COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL 
Oppe M, Al MJ, Rutten-van Mölken MP
Erasmus MC, Rotterdam, The Netherlands 
MO4  TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE THE NETHERLANDS 
Joore MA1, Tjan Heijnen V1, Severens JL1, Novák A2, Oron U3, Pompen M3, Essers BA1
1University Hospital Maastricht, Maastricht, The Netherlands, 2Anovák-Services, Apeldoorn, The Netherlands, 3Roche Netherland BV, Woerden, The Netherlands 
 
Quality of Life/Preference-Based Measures II
QL5  COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS 
Maes IH1, Joore MA1, Cima RF2, Vlaeyen JW2, Anteunis LJ1
1University Hospital Maastricht, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The Netherlands 
QL6  ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS 
Narvilkar P, Mahajan A, Dimri S, Kumar R, Sehgal M
Heron Health Private Ltd, Chandigarh, India 
QL7  INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES 
McKenna SP1, Twiss J1, Meads DM1, Revicki D2, Pokrzywinski R3, Gale R4
1Galen Research, Manchester, UK, 2United BioSource Corporation, Bethesda, MD, USA, 3United Biosource Corporation, Pittsburgh, PA, USA, 4Novartis AG, Horsham, UK 
QL8  COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD 
Lai JS1, Cook K2, Stone A3, Beaumont J4, Cella D4
1Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, USA, 2University of Washington, Houston, TX, USA, 3Stony Brook University, Stony Brook, NY, USA, 4Evanston Northwestern Healthcare, Evanston, IL, USA 
 
Podium Session III
Monday 10 November 2008, 11:30-12:30
Health Care Decisions Using Outcomes Research Case Studies
CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND
Zagorska A1, Krol Z1, Lipska I1, Falek A2, Sauvage P3, Barna A3, van Ormondt T4
1Agency for Health Technology Assessment, Warszawa, Poland, 2Ministry of Health, Warszawa, Poland, 3Ministry of Health, Paris, France, 4Law Online - EU expert, Leiden, The Netherlands
CASE2 DO TECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS
Goeree RA
Ontario Health Technology Advisory Committee (OHTAC), Hamilton, ON, Canada
CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND: AIMING AT VALUE-BASED PRICING.
Hauksdottir R1, Björnsdottir I2, Kanavos P3
1Icelandic Medicine Pricing and Reimbursement Committee, Reykjavik, Iceland, 2Bifröst University, Borgarnes, Iceland, 3London School of Economics, London, UK
   
Cancer Economic Evaluations I 
CN1  PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER CENTER 
Miller LA, Lau J, Lal LS, Arbuckle R
University of Texas - MD Anderson Cancer Center, Houston, TX, USA 
CN2  ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT: AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASIS IN THE UK. 
Gauthier A1, Gennari A2, Martin M3, Maetzel A4
1i3 Innovus, Uxbridge, UK, 2National Cancer Research Institute, Genoa, Italy, 3i3 Innovus, Uxbridge, Middlesex, UK, 4Amgen (Europe) GmbH / University of Toronto, Zug, Switzerland 
CN3  COST OF INITIAL PROSTATE CANCER TREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE: ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY AND SPAIN 
Benedict Á1, Black L2, Stokes ME3
1United BioSource Corporation, Budapest, Hungary, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3United BioSource Corporation, Dorval, QC, Canada 
CN4  YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUE TO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS—UNITED STATES, 2003 
Ekwueme DU1, Chesson HW1, Zhang KB2, Balamurugan A3
1U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Macro International Inc, Bethesda, MD, USA, 3Arkansas Department of Health, Little Rock, AR, USA 
 
Infectious Disease Economic Evaluations 
IN1  COST EFFECTIVENESS ANALYSIS OF REYATAZ® VERSUS KALETRA® IN THE TREATMENT OF NAÏVE HIV PATIENTS IN ITALY 
Thuresson PO1, Heeg B1, Neubauer AS2, Intorcia M3, Van Hout BA1
1Pharmerit BV, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Munich, Germany, 3Bristol-Myers Squibb, Rome, Italy 
IN2  MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM 
Lescrauwaet B1, Nevens F2, Zammit D1, Yuan Y3, Hay JW4
1Bristol-Myers Squibb, Braine l'Alleud, Belgium, 2UZ Gasthuisberg KULeuven, Leuven, Belgium, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4University of Southern California, Los Angeles, CA, USA 
IN3  PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY 
Kanbur B1, Azap A2, Arat M2, Sarioz F1, Tatar F1
1Janssen-Cilag, Istanbul, Turkey, 2Ankara University, Ankara, Turkey 
PIN44

IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM: 48-WEEK FINDINGS FROM POOLED DUET TRIALS

 

Martin SC1, Spaepen E2, Corbett CJ3, De Smedt G3
 

1Johnson & Johnson Pharmaceutical Services, LLC, Mechelen, Belgium, 2SBD Analytics, Bekkevoort, Belgium, 3Tibotec-Virco, Mechelen, Belgium

Muscular-Skeletal Disease Evaluations
MS1  PREVALENCE OF FIBROMYALGIA IN EUROPE- A TIP OF THE ICEBERG.RESULTS FROM A LARGE-SCALE SURVEY 
Le Lay K1, Branco J2, Bannwarth B3, Matucci Cerinic M4, Blotman F5, Spaeth M6, Carbonell JA7, Failde I8, Saraiva F9, Nacci F4, Thomas E5, Boussetta S1, Taieb C1
1Pierre Fabre, Boulogne, France, 2CHLO, EPE/Hospital Egas Moniz, Lisboa, Portugal, 3Université V. Segalen, Bordeaux, France, 4Univ. Firenze, Florence, Italy, 5Lapeyronie Hospital, Montpellier, France, 6Unit Rheumatology, Munich, Germany, 7Hospital de la Esperanz, Barcelona, Spain, 8Universidad de Cadiz, Cadix, Spain, 9Hospital Santa Maria, EPE, Lisboa, Portugal 
MS2  LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES 
Nadjar A1, Le Gal M1, Mainguy Y2, Le Lay K3, Taieb C3
1MAPI Research Institute, Lyon, France, 2Pierre Fabre Laboratories, Labège, France, 3Pierre Fabre, Boulogne, France 
MS3  POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UK 
Hauber AB1, McCrink L2, Beard S2, Garcia-Cebrian A3, Maas G4, Das Gupta R5, Le TK6
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK, 3Eli Lilly and Company Limited, Basingstoke, UK, 4Boehringer Ingelheim GmbH, Ingelheim, Germany, 5Boehringer Ingelheim, Bracknell, Berkshire, UK, 6Eli Lilly and Company, Indianapolis, IN, USA 
MS4  GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY 
Braun J1, Inman RD2, van der Heijde D3, Mack M4, Parasuraman S5, Buchanan J5, Hsu B4, Beutler A4, Han C5, Deodhar A6
1Rheumazentrum Ruhrgebiet, Herne, Germany, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, The Netherlands, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 6Oregon Health and Science University, Portland, OR, USA 
   
Quality of Life/Prefence-Based Measures III 
QL9  DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) 
Tiplady B1, Carrington R2, Battersby C3, Wilson K4, Cummings G5, Lyle D5, Ralston S4
1PRO Consulting, London, UK, 2AstraZeneca R & D Charnwood, Loughborough, UK, 3AstraZeneca R & D Alderley Park, Macclesfield, UK, 4University of Edinburgh, Edinburgh, UK, 5Wellcome Trust Clinical Research Facility, Edinburgh, UK 
QL10  DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE 
Cuervo J1, Rebollo P1, Zardain PC1, Tranche S2, Barreda MJ2, Prieto MA2, Sánchez-Baragaño M2
1BAP Health Outcomes Research, Oviedo, Spain, 2SESPA, Oviedo, Spain 
QL11  FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS 
Hazes M1, Purcaru O2, Coteur G3, Mease P4
1Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands, 2UCB, Braine l'Alleud, Belgium, 3UCB, Braine L'Alleud, Belgium, 4Seattle Rheumatology Associates, Seattle, WA, USA 
QL12  FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE 
Chachuat A1, Koltowska-Haggstrom M2, Gilet H3, Auziere S4, Guillaume X4, Arnould B3, Viala M3
1Pfizer, Paris, France, 2KIMS Medical Outcomes, Pfizer Endocrine Care, Sollentuna, Sweden, 3Mapi Values, Lyon, France, 4TNS-Healthcare, Montrouge, France 
 
Podium Session IV
Monday 10 November 2008, 14:00-15:00
Arthritis Outcomes Measurement 
AR1  PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS 
Braakman-Jansen LM1, Taal E1, Kuper I2, van de Laar MA2
1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente Hospital, Enschede, The Netherlands 
AR2  A COST EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM THE STURE REGISTRY 
Lekander I1, Borgström F1, Carli C2, Svarvar P3, Ljung T3, van Vollenhoven R2
1i3 Innovus, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Schering-Plough AB, Stockholm, Sweden 
AR3  TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS 
Adams R1, Ng CT2, Gibbs A3, Bresnihan B4, Veale D5, Tilson L1, FitzGerald O5, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2St.Vincents University, Dublin, Ireland, 3Galway Clinic, Galway, Ireland, 4St Vincents University Hospital, Dublin, Ireland, 5St.Vincents University Hospital, Dublin, Ireland 
AR4  MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS 
Kim MM, Pahira J, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA 
 
Cancer Economic Evaluations II 
CN5  EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UK 
Gyldmark M1, Gatzemeier U2, Nicolson M3, Latimer N4, Walzer S5
1F Hoffmann La Roche, Basel, Switzerland, 2Hospital Grosshansdorf, Grosshansdorf, Germany, 3Royal Infirmary Aberdeen, Aberdeen, UK, 4Roche Products Ltd, Welwyn Garden City, UK, 5F. Hoffmann - La Roche Ltd, Basel, Switzerland 
CN6  COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING A TRANSMISSION DYNAMIC MODEL 
Usher C1, Tilson L1, Olsen J2, Rudbeck Jepsen M3, Walsh C4, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2University of Southern Denmark, Odense, Denmark, 3Statens Serum Institut, DK-2300 Copenhagen S, Denmark, 4Trinity College Dublin, Dublin, Ireland 
CN7  MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER: THE CASE OF PARTICLE THERAPY 
Grutters JP1, Pijls-Johannesma M1, De Ruysscher D1, Dekker AL1, Peeters A1, Severens JL2, Lambin P1, Joore MA2
1Maastro Clinic, Maastricht, The Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands 
CN8  AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE 
Nagy B1, Kutikova L2, Stastny M2, Vasile K3, Zsolnai Nagy I4, Mayer J5
1Healthware Consulting Ltd, Budapest, Hungary, 2Bristol-Myers Squibb, Prague, Czech Republic, 3Bristol-Myers Squibb, Bucharest, Romania, 4Bristol-Myers Squibb, Budapest, Hungary, 5University Hospital Brno, Brno, Czech Republic 
 
Diabetes Economic Impact 
DB1  ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UK: A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS 
Smith HT1, Valentine WJ2, Boye KS3, Kalsekar A3, Pratoomsoot C2
1Eli Lilly and Company, Surrey, UK, 2IMS Health, Basel, Switzerland, 3Eli Lilly and Company, Indianapolis, IN, USA 
 
PDB36  COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA 
Minshall ME1, Swan T2, Slusarek B2, Ikramuddin S2
1IMS Health, Noblesville, IN, USA, 2University of Minnesota, Minneapolis, MN, USA 
   
DB3  HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REAL WORLD CONDITIONS IN GERMANY: LIVE-SPP STUDY 
Schöffski O1, Dippel FW2, Breitscheidel L3, Benter U3, Müller M4, Volk M4
1Universität Erlangen-Nürnberg, Nürnberg, Germany, 2Sanofi-Aventis Germany GmbH, Berlin, Germany, 3Kendle GmbH, Munich, Germany, 4axaris software&systeme GmbH, Ulm, Germany 
DB4  COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES 
Hammer M1, Lammert M2, Frier BM3
1Novo Nordisk A/S, Bagsværd, Denmark, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 3Royal Infirmary of Edinburgh, Edinburgh, UK 
 
Health Policy Issues and Implications 
HP1  ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007 
Seoane-Vazquez E1, Rodriguez-Monguio R2
1The Ohio State University, Columbus, OH, USA, 2University of Massachusetts, Amherst, MA, USA 
HP2  NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE: FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST 
Hatzikou M1, Alexopoulos E2, Chatzistamatiou Z3, Geitona M1
1University of Thessaly, Volos, Greece, 2University of Patras, RIO, Greece, 3Alexandra General Hospital, Neo Faliro, Greece 
HP3  TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE 
Guelfucci F1, François C2, Milea D2, Saragoussi D2, Toumi M3
1Altipharm, Paris, France, 2Lundbeck SAS, Paris, France, 3Université Lyon I, Villeurbanne, France 
HP4  THE IMPACT OF A MEDICAID EXPANSION TO INCLUDE POPULATION WITH LOW INCOME ON THE PREVENTABLE HOSPITALIZATIONS 
Shin H, Kim S
Health Insurance Review & Assessment Service, Seoul, South Korea 
   
Outcomes Research Issues
OR1  EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS 
Conlon J1, Xu X2, Zlateva G3, Knight T2
1Covance, Inc, Princeton, NJ, USA, 2Covance Market Access Services Inc, Gaithersburg, MD, USA, 3Pfizer, Inc, New York, NY, USA 
OR2  INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS 
ter Borg J1, Al MJ2
1IMS Health, Den Haag, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands 
OR3  ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS: DEVELOPMENT AND APPLICATION OF A TOOLKIT 
De Wit GA, Tariq L, Wong A, Polder JJ, van Baal P
National Institute of Public Health and the Environment, Bilthoven, The Netherlands 
 
PMC23  WHAT IS POLITICIAN'S AND CLINICIAN'S WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENT VALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES 
Soini EJ1, Kukkonen J2, Myllykangas M3, Ryynänen OP4
1ESiOR Oy, Department of Health Policy and Management, and Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 2Kuntohovi Spa, Joensuu, Finland, 3University of Kuopio, Kuopio, Finland, 4University of Kuopio and Kuopio University Hospital, Kuopio, Finland 

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.